A Humanized Tumor Necrosis Factor Receptor 1 (TNFR1)-specific Antagonistic Antibody for Selective Inhibition of Tumor Necrosis Factor (TNF) Action
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Tumor necrosis factor (TNF) is a recognized pathogenic mediator in a number of chronic and acute inflammatory diseases. Antibodies targeting TNF have significantly improved therapy of chronic inflammatory diseases, in particular rheumatoid arthritis. Despite this success, anti-TNF treatment shows clinical efficacy only in part of the patients and is often transient, necessitating the development of alternative reagents to combat TNF action. We here describe humanization and functional properties of a TNFR1-specific, monovalent antibody fragment, designated IZI-06.1, which binds to the cysteine-rich domain 1 of TNFR1 with high affinity and competes ligand binding. IZI-06.1 serves as a receptor-selective inhibitor of proapoptotic and antiapoptotic TNF actions, revealed from complete blockage of TNFR1-dependent apoptosis and interleukin-6 induction in Kym 1 and HeLa cells, respectively, whereas TNFR2-mediated signals remained intact, evident from TNF and interleukin-2-mediated costimulation of interferon-gamma production in T cells. Accordingly, IZI-06.1 is a TNFR1-selective TNF antagonist and holds great promise to be developed into a clinically applicable therapeutic. IZI-06.1 could be a useful therapeutic alternative in all diseases already known to clinically respond to anti-TNF treatment and particularly in those diseases, where anti-TNF treatment has failed because of complete blockade of TNF action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793 · cited 2×
“demonstrated in numerous models including TNFR knockout mice that TNFR1 is the major mediator of TNF’s pathologic phenotypes.(1,2) In several chronic inflammatory diseases, presently 3 drugs are approved that interfere with the TNF signal: Remicade, Enbrel, and Humira.”
BackgroundMethodTNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
A Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling
Chan, F. K.-M., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L., & Lenardo, M. J. (2000) · Science · doi:10.1126/science.288.5475.2351 · Cited by 856
Cited by
TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects
Probert, L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.038 · Cited by 495
Post-stroke inflammation—target or tool for therapy?
Lambertsen, K. L., Finsen, B., & Clausen, B. H. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1930-z · Cited by 465
Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration
van Dijk, G., van Heijningen, S., Reijne, A. C., Nyakas, C., van der Zee, E. A., & Eisel, U. L. M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00173 · Cited by 75
Zhang, N., Wang, Z., & Zhao, Y. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.03.002 · Cited by 72
Alterations in bone fracture healing associated with TNFRSF signaling pathways
Dong, Y., Zhou, H., Alhaskawi, A., Wang, Z., Lai, J., Abdullah Ezzi, S. H., Kota, V. G., Abdulla Hasan Abdulla, M. H., Sun, Z., & Lu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905535 · Cited by 9
Metadata
- Authors
- Kontermann, R. E., Münkel, S., Neumeyer, J., Müller, D., Branschädel, M., Scheurich, P., & Pfizenmaier, K.
- Venue
- Journal of Immunotherapy
- Published
- 2008-04
- Volume
- 31
- Issue
- 3
- Pages
- 225-234
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W2075128152
- Cited by
- 43
- References
- 3
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Humanized Tumor Necrosis Factor Receptor 1 (TNFR1)-specific Antagonistic Antibody for Selective Inhibition of Tumor Necrosis Factor (TNF) Action. https://app.cochat.ai/papers/10.1097/cji.0b013e31816a88f9
- The paper
- Kontermann, R. E., Münkel, S., Neumeyer, J., Müller, D., Branschädel, M., Scheurich, P., & Pfizenmaier, K. (2008). A Humanized Tumor Necrosis Factor Receptor 1 (TNFR1)-specific Antagonistic Antibody for Selective Inhibition of Tumor Necrosis Factor (TNF) Action. Journal of Immunotherapy. https://doi.org/10.1097/cji.0b013e31816a88f9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.